Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Chemotherapy plus BCG Immunotherapy with or without Allogeneic Tumor Cells for Acute Myeloid Leukemia

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
No phase specified Treatment Closed no age specified SWE-LGMS-AML-1

Objectives

I.  Evaluate the effect of the addition of BCG immunotherapy with and without 
allogeneic leukemic cells to an earlier chemotherapy regimen for acute myeloid 
leukemia.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with acute myeloid leukemia.

Expected Enrollment

Protocol closed 12/80.

Outline

Study randomized for Maintenance only.
Induction:
2-Drug Combination Chemotherapy.  Daunomycin, DNR, NSC-82151 or Daunomycin-DNA 
complex, NSC-169533; Cytosine arabinoside, ARA-C, NSC-63878.
Maintenance:
Arm I:  Immunotherapy plus 2-Drug Combination Chemotherapy.  BCG-Glaxo, BCG; 
live allogeneic leukemic cells; DNR (or Daunomycin-DNA complex); ARA-C.  Arm 
active 1974-1978.
Arm II:  2-Drug Combination Chemotherapy.  DNR (or Daunomycin-DNA complex); 
ARA-C.  Arm active 1974-1978.
Arm III:  Immunotherapy plus 2-Drug Combination Chemotherapy.  BCG; DNR (or 
Daunomycin-DNA complex); ARA-C.  Arm active 1978.
Arm IV:  Immunotherapy plus Single-agent Chemotherapy and Leucovorin Rescue.  
BCG; live allogeneic leukemic cells; plus (a) early Intensification with 
high-dose Methotrexate, MTX, NSC-740 and Citrovorum Factor, CF, NSC-3590 or 
(b) no early Intensification.  Arm active 1978.

Trial Contact Information

Trial Lead Organizations

Karolinska University Hospital - Huddinge

Peter Reizenstein, MD, Protocol chair(Contact information may not be current)
Ph: 46-8-585-800-00

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.